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Abstract
Background: Detailed knowledge of the molecular and cellular mechanisms that direct spatial and temporal gene
expression in pre-implantation embryos is critical for understanding the control of the maternal-zygotic transition
and cell differentiation in early embryonic development. In this study, twenty-three clones, expressed at different
stages of early mouse development, were identified using differential display reverse transcription polymerase
chain reaction (DDRT-PCR). One of these clones, which is expressed in 2-cell stage embryos at 48 hr post-hCG
injection, shows a perfect sequence homology to the gene encoding the granzyme G protein. The granzyme
family members are serine proteases that are present in the secretory granules of cytolytic T lymphocytes.
However, the pattern of granzyme G expression and its function in early mouse embryos are entirely unknown.
Results: Upon the introduction of an antisense morpholino (2 mM) against granzyme G to knock-down
endogenous gene function, all embryos were arrested at the 2- to 4-cell stages of egg cleavage, and the de novo
synthesis of zygotic RNAs was decreased. The embryonic survival rate was dramatically decreased at the late 2-cell
stage when serine protease-specific inhibitors, 0.1 mM 3,4-dichloroisocoumarin (3,4-DCI), and 2 mM phenyl
methanesulphonyl fluoride (PMSF), were added to the in vitro embryonic culture medium. Survival was not
affected by the addition of 0.5 mM EDTA, a metalloproteinase inhibitor.
Conclusion: We characterized for the first time the expression and function of granzyme G during early stage
embryogenesis. Our data suggest that granzyme G is an important factor in early mouse embryonic development
and may play a novel role in the elimination of maternal proteins and the triggering of zygotic gene expression
during the maternal-zygotic transition.
Background
Mammalian embryonic development at pre-implantation
stages involves rapid cell proliferation and the earliest
phases of cell differentiation. Fertilization triggers the
completion of meiotic division in the oocyte, induces
embryonic processes such as the degradation of mater-
nal RNAs and proteins, and activates the embryonic
genome for the maternal-zygotic transition (MZT). It
has been proposed that the activation of the embryonic
genome begins at the 2-cell stage in mouse embryos,
the 4- to 8-cell stage in human embryos, and the 8- to
16-cell stage in rabbit and sheep embryos [1]. Early
genes such as Zar1 [2], ezrin [3], hsp70.1 [4], and
U2afbp-rs [5] may play important roles in embryonic
genome activation. Previous work has suggested that the
acquisition of a transcriptionally repressive environment
and changes in the chromatin structure caused by
alterations in histone deacetylase activity can block or
stimulate the repression of markers of genome activa-
tion [6,7]. However, the transition of the control from
the maternal to the embryonic genome in early mam-
malian embryos is still not fully understood.
As a first step towards the elucidation of factors
important for the proper functioning of early mouse
embryonic development, we used the differential display
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PCR) method [8,9] to compare two or more mRNA
samples prepared from small amounts of tissue. This
method is particularly suitable for developmental studies
that involve temporal changes in gene expression in
pre-implantation embryos. Genes that are temporally
and differentially expressed in mouse embryos have
been identified using this technique [10,11]. In the cur-
rent study, tweenty-three mRNA molecules that are dif-
ferentially expressed in unfertilized eggs, 2-cell, or 4-cell
embryos were detected. One of these clones, expressed
in 2-cell stage embryos at 48 hr post-hCG injection, has
perfect sequence homology with the gene encoding
granzyme G.
The expression of members of the granzyme gene
family of proteins (granzymes A-H, K, M), which encode
serine proteases, has been documented in the secretory
granules of cytolytic T lymphocyte lines [12]. Granzymes
D, E, F, and G have also been shown to be expressed at
gestation in the mouse uterus during the process of
decidualization, in which rapid uterine cell growth and
differentiation occurs [13]. The decidual reaction is pri-
marily characterized by the differentiation of stromal
fibroblasts into decidual cells and by the proliferation
and differentiation of the granulated metrial gland
(GMG) cells [14]. Murine GMG cells belong to the nat-
ural killer (NK) cell lineage [15-17], and an analogous
cell type, the endometrial granulocyte, has been identi-
fied in humans [18]. In the mouse, GMG cell differen-
tiation begins at about day 7 of gestation and manifests
via the accumulation of cytolytic mediators, including
perforin and granzymes A-H, within cytoplasmic gran-
ules. GMG cells have been proposed to regulate tropho-
blast invasion into maternal deciduas. Indeed,
trophoblast killing by murine and human uterine NK
cells has been reported [19,20]. Nevertheless, the expres-
sion of granzyme G and its function in early embryos
are entirely unknown.
In this study, the function of granzyme G during early
embryonic development was elucidated using morpho-
lino oligonucleotides to knock-down granzyme G-speci-
fic mRNA translation and granzyme-specific serine
protease inhibitors to inhibit protein activity in an in
vitro culture system. The embryo survival rate, cleavage
rate, 2-cell developmental block effect, and inner cell
mass (ICM) morphology were evaluated extensively.
Results
Identification of differentially expressed genes in mouse
embryos during early developmental stages
For DDRT-PCR, ten different random primers and four
anchor primers were used in 40 unique combinations.
For templates, total RNA was prepared from various
stages of developing embryos post-hCG injection.
Thirty-one of the forty random-anchor primer combina-
tions produced DDRT-PCR patterns that were identical,
irrespective of the developmental stage of the mouse
embryos (data not shown). Only nine random-anchor
primer combinations detected transcripts that were
clearly differentially expressed. Representative DDRT-
P C Rp a t t e r n sa r es h o w ni nF igure 1. Transcripts that
were clearly differentially expressed at a particular egg
cleavage stage were identified for further analysis. A
total of tweenty-three such bands were isolated, includ-
ing six cDNA clones in unfertilized eggs, twelve cDNA
clones in 2-cell embryos, and five cDNA clones in 4-cell
embryos (Table 1). The size of these bands ranged from
250 to 870 bp.
Figure 1 Representative profiles of differential display mRNAs at various stages of mouse development.P o l y m e r a s ec h a i nr e a c t i o n
amplicons were amplified using the primer sets of (A) random primer H-AP3 and anchor primer T11G, and (B) random primer H-AP8 and
anchor primer T11G. Mouse embryos at the unfertilized oocyte (OC), two-cell embryo (2-C), and four-cell embryo (4-C) stages were used in this
study and are shown at the top of each lane. Differentially displayed bands are marked by arrows.
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Page 2 of 16Purification and sequencing of cDNAs from differential
display amplicons
To further characterize the differentially expressed
embryonic transcripts, the bands were excised from
the gel for PCR re-amplification using the same primer
combinations that had led to their initial identification.
In all cases, PCR re-amplification was successful, and
t h es i z eo ft h es u b s e q u e nt PCR products matched
those of the original DDRT-PCR products. The PCR
amplicons were cloned and subjected to sequence ana-
lysis. In a comprehensive search of the GenBank data-
base, the sequences of eight of the cDNA clones
matched perfectly with known mouse genes: granzyme
G, methylenetetrahydrofolate dehydrogenase (Mthfd1),
TAF9B RNA polymerase II, LSM14 homlog A (SCD6),
N-deacetylase/N-sulfotransferase 4 (Ndst 4), the ATP-
dependent chromatin remodeling protein SNF2H,
high-mobility group box 1 (Hmgb1), and the TATA-
box binding protein-associated factor (Taf9)( T a b l e1 ) .
Another group of 15 cDNA clones showed high
sequence homology (60-87%) with existing mouse
genes, and may represent novel members of these gene
families. As the granzyme G gene is known to encode
a serine protease that is present in the secretory gran-
ules of cytolytic T lymphocyte lines and granzymes D-
G are also expressed during late gestation in the
mouse uterus, we thought it would be worthwhile to
investigate whether granzyme G had a novel, specific
function in early embryonic development.
Granzyme G gene expression profiling at different mouse
developmental stages
To verify the authenticity of the DDRT-PCR-derived
cDNA sequences, gene-specific primers were designed
based on published and experimentally derived
sequences of the granzyme G gene for direct RT-PCR
detection. Transcripts of the granzyme G gene were
detected at the 2-cell stage, but were absent at the
o o c y t e ,1 - c e l l ,9 6h r ,a n dl a t e rs t a g e s( F i g u r e2 A ) .T h e
direct RT-PCR results were therefore consistent with
the DDRT-PCR data. The spatial expression of gran-
zyme G during developmental stages was subsequently
examined and was determined to be confined to the
extra-embryonic trophoblasts during the middle implan-
tation stage (D10-14) of the mouse placenta (Figure 2B).
The temporally constrained expression of granzyme G
was further confirmed by whole-mount embryo in situ
hybridization using a cloned granzyme G gene-specific
fragment as a probe. The results consistently showed a
high expression level at the 2-cell stage, which quickly
diminished through the 4-cell stage (Figure 3). Further-
more, the granzyme G protein localized in the cyto-
plasm of 2-cell stage (Figure 4A) and 4-cell stage
(Figure 4B) embryos, as demonstrated by whole-mount
Table 1 Differential display mRNAs identified from early mouse embryos by DDRT-PCR analysis
Stage dbEST ID GenBank AccN
† Description
Oocyte 7302701 BF733166 AC133163.2: Mus musculus chromosome 9 clone RP24-338G17.
7302702 BF733167 NT_039260.7: Mus musculus chromosome 4 genomic contig, tyrosinase-related protein 1
7302703 BF733168 NT_166285.1: Mus musculus chromosome 3 genomic contig, 226046 bp at 5’ side: hypothetical protein
7302704 BF733169 NT_039424.7: Features in this part of subject sequence: ubiquitin protein ligase E3A isoform 2
7302706 BF733171 NM_001001176.1: Mus musculus TATA box binding protein (TBP)-associated factor 9 (Taf9)
2-Cell 6920934 BF440092 AL845157.7: Ortholog of H. sapiens chromosome 2open reading frame 25 (C2orf25) and part of a novel gene
6920935 BF440093 AG509034: Mus musculus molossinus DNA, clone: MSMg01- 412D07.T7, genomic survey sequence
6920936 BF440094 AL670999: Contains the (pseudo) gene for a novel protein similar to high-mobility group box 1 (Hmgb1)
6920937 BF440095 NM_001001176: Mus musculus TAF9B RNA polymerase II
6920938 BF440096 AC109179: Mus musculus chro. 18 from clone RP23-382N7
6920939 BF440097 NT_039240.7: Ndst4; N-deacetylase/N-sulfotransferase (heparinglucosaminyl) 4
6920940 BF440098 AC206551.4: Pongo abelii BAC clone CH276-44A10 from chromosome 15, complete sequence
6920941 BF440099 NM_025948.2: Mus musculus LSM14 homolog A (SCD6,S.cerevisiae)
6920942 BF440100 BC054388: Mus musculus ribosomal protein L37
6920943 BF440101 AC068254.6: Homo sapiens chromosome 18, clone RP11-543H23, complete sequence.
6920944 BF440102 BT043574.1: Salmo salar clone HM4_2567 membrane protein palmitoylated 1 mRNA, complete cds.
7302695 BF733160 J02872: Mouse granzyme G mRNA
4-Cell 7302696 BF733161 NT_039471.7: Mus musculus chromosome 9 genomic contig, strain C57BL/6J
7302697 BF733162 AF375046: Mus musculus ATP-dependent chromatin remodeling protein SNF2 H mRNA
7302698 BF733163 AK076019: Mus musculus Methylenetetrahydrofolate dehydrogenase (Mthfd1)
7302699 BF733164 NM_001001984.2: Mus musculus lysine (K)-specific demethylase 2A
7302700 BF733165 AC198183.2: Nomascus leucogenys BAC clone CH271-340F4 from chromosome unknown, complete sequence
† All of the new identified mouse embryonic cDNA sequences were deposited in GenBank.
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Page 3 of 16immunofluorescence. The protein completely disap-
peared by the 16-cell stage (Figure 4C).
Antisense morpholino knock-down of granzyme G
expression blocks embryos at the two-cell stage
To understand the function and importance of the gran-
zyme G gene product during early embryonic stages, we
introduced an antisense morpholino oligonucleotide
(MO) against granzyme G into mouse embryos at the
pronuclear stage. As a control, nonsense morpholino
was conjugated to a FITC fluorophore and microin-
jected into 1-cell stage embryos. Preliminary tests
showed that the control FITC-conjugated morpholino
molecules distributed equally into dividing cells and
were stably maintained until the blastocyst stage.
Embryonic development was not affected after treatment
with the control morpholino at doses between 1 and 20
mM (Figure 5A). When 2 mM granzyme G antisense
morpholino was microinjected into the cytoplasm of 1-
cell embryos, early development arrested at the 2- to 4-
cell stages. Only 11.6% of treated embryos overcame 2-
cell arrest and developed into 4-cell stage embryos. In
contrast, the survival rate of embryos treated with 2
mM control morpholino, M2 buffer-injected embryos,
and control in vitro cultured embryos was 93.3%, 85%,
and 94.6%, respectively (Table 2).
Developmental potential changes in response to
granzyme G morpholino antisense treatment in a dose-
dependent manner
Microinjection of serially diluted granzyme G morpho-
linos (2 mM, 0.2 mM, 0.02 mM, and 0.002 mM) into
the cytoplasm of pronuclear mouse embryos resulted
in survival rates to the blastocyst stage of 0%, 33.3%,
95.6%, and 87.2%, respectively (Table 3). The dose-
response effect of the anti-granzyme G morpholino
clearly correlated with the embryonic development
potential.
To determine the efficacy of the morpholino knock-
down, the amount of granzyme G mRNA remaining
after treatment was quantified. Total RNA isolated from
different MO-treated 2-cell stage embryos was first
digested with RNase III, followed by first-strand cDNA
synthesis and semi-quantitative RT-PCR. For the pro-
nuclear stage embryos injected with the intermediate
dose (0.2 mM) of anti-granzyme G morpholino, the
amount of intact granzyme G mRNA at the late 2-cell
stage was reduced to 23% of the amount observed in
Figure 2 Temporal and spatial expression of granzyme G mRNA during early embryonic development. (A) RT-PCR confirmation of the
temporally expressed granzyme G gene identified by DDRT-PCR in 2-cell stage embryos. Mouse embryos were collected at unfertilized oocyte
(OC), one-cell (1-C), two-cell (2-C), four-cell (4-C), eight-cell (8-cell), morula (MO), and blastocyst (BL) stages. Pregnant mouse uterine (UT) GMG
cell mRNA was used as a positive control. (B) Stage-specific expression of granzyme G in the extraembryonic trophoblast during early
implantation (D6-D8), middle implantation (D10-14), and late implantation (D16-20). A b-actin primer set was used as an internal control. The
results are representative of three experiments.
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Page 4 of 16normal untreated embryos, 2 mM control MO-treated
embryos, and M2 buffer-injected embryos. For embryos
treated with the high dose of granzyme G morpholino
(2 mM), no granzyme G mRNA could be detected, pre-
sumably as a consequence of MO blocking and RNase
III digestion (as shown in Figure 5B). We expect that
this effect reflects the developmental arrest in 2-cell
stage embryos.
Interestingly, the number of blastomere cells were sig-
nificantly decreased in blastocysts treated with a low-
dose of granzyme G morpholino (0.2 mM) when com-
pared to normally developed blastocysts (43 ± 5 vs. 97 ±
8, p < 0.01; Figure 6). The inner cell mass (ICM) of trea-
ted blastocysts also exhibited a dispersed distribution
compared to the localized ICM cluster of control blasto-
cysts (Figure 6, A-D). Finally, the ICM of the 0.2 mM
granzyme G MO-treated embryos also showed a dra-
matic decrease in differential staining compared to nor-
mally developed blastocysts (18 ± 5 vs. 37 ± 4, p < 0.05;
Figure 6E).
Maternal-zygotic transition inhibited by granzyme G
knock-down
Bromouridine, which substitutes bromine to uridine,
was used to trace zygotic gene expression during the
maternal-zygotic transition (MZT). After its incorpora-
tion into cells, bromouridine is converted to Br-UTP.
During transcription, converted Br-UTP is recognized as
Figure 3 Whole-mount embryo in situ hybridization (ISH) using a FITC-conjugated granzyme G oligonucleotide probe at different
stages of normal mouse development. (A to C) One-cell stage mouse embryos. (D to F) Two-cell stage mouse embryos. (G to I) Four-cell
stage mouse embryos. (J to K) Eight-cell stage mouse embryos. The left panels (A, D, G, and J) show embryos photographed under phase
contrast imaging. The middle panels (B, E, H, and K) show embryos stained with Hoechst 33342 for DNA localization (blue) under fluorescence
microscope observation. The right panels (C, F, I, and L) show embryos hybridized with a granzyme G oligonucleotide probe (green) under
confocal microscopic observation. Scale bar: 30 μm.
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Page 5 of 16the same substrate as UTP and is incorporated into nas-
cent RNAs. Confocal images of embryos were observed
in bright field (Figure 7A-D) and under fluorescence
(Figure 7E-H). Quantitative data showed that embryos
microinjected with 2 mM granzyme G morpholino (Fig-
ure 7I) exhibited decreased zygotic gene transcription.
Specifically, the newly synthesized zygotic RNA was less
than 50% of the normal control embryos (Figure 7K).
Moreover, the treatment of embryos with the control
morpholino at the same concentration (Figure 7J) did
not affect zygotic RNA synthesis compared to normal
control embryos.
Figure 4 Immunoflourescence staining of Granzyme G protein expression and subcellular localization at different stage embryos. (A)
Two-cell stage mouse embryos (n = 6). (B) Four-cell stage mouse embryos (n = 6). (C) Sixteen-cell stage mouse embryos (n = 5). The left panels
show embryos stained with a granzyme G-specific primary antibody and FITC-conjugated secondary IgG antibody. The middle panels show
embryos stained with DAPI for nuclear localization. The right panels show merged images of grazyme G and DAPI staining.
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Page 6 of 16The effect of serine protease inhibitors on embryo
survival rate
Serine protease-specific inhibitors were used in the in
vitro culture system to evaluate the effect of granzyme
G activity suppression on embryonic development. The
embryonic survival rate was dramatically reduced at the
late 2-cell stage (3% and 12%) in the presence of 0.1
mM 3,4-dichloro-isocoumarin (3,4-DCI) and 2 mM phe-
nyl methanesulphonyl fluoride (PMSF), respectively. Due
to the short life of PMSF activity, three different stages
Figure 5 Dosage and stability tests of antisense morpholinos in mouse embryos. (A) The developmental potential of embryos was
evaluated using 1-20 mM doses of control nonsense MO, which was conjugated to FITC fluorescent dye and microinjected into the cytoplasm
of pronuclear-stage embryos. Upper panel: Phase contrast images. Lower panel: Fluorescence images. >Scale bar: 30 μm. (B) Granzyme G mRNA
blocking efficiency test following microinjection of different doses of granzyme G-specific antisense MO (0, 0.2, and 2 mM) into 1-cell stage
embryos. Total RNA was isolated from 2-cell stage experimental embryos, followed by RNase III digestion, purification, and subjection to RT-PCR
analysis. In the control panel, mRNA extracted from the control MO-injected embryos was used as an un-blocked control (lane 5), mRNA from
pregnant mouse uterine GMG cells was used as a positive control (Pos; lane 6), and reverse transcriptase-omitted mRNA template was used as a
negative control (Neg; lane 7). The results are representative of three experiments.
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Page 7 of 16(pronuclear, 2-cell, and 8-cell) of mouse embryos were
supplemented one time with 2 mM PMSF in the culture
medium. PMSF inhibits survival only at the 2-cell stage,
when granzyme G exhibits serine protease activity in the
embryos. However, the addition of other kinds of metal-
loproteinase inhibitors, such as 0.5 mM EDTA, had no
obvious consequence, as survival rates of > 90% to the
late 2-cell stage and 60% to the blastocyst stage were
observed (Figure 8). The addition of 1% DMSO solvent,
as a vehicle control, did not interfere wuth mouse
embryo survival, especially in the maternal-to-zygotic
transition at the 2-cell stage (Figure 8).
Discussion
Normal embryonic development, as well as many
genetic disorders and cancers, involves a delicate bal-
ance between the processes of cellular differentiation
and proliferation. Many developmental genes have been
identified as candidate genes for cancers or other forms
of human disorders, and may be developed into novel
diagnostic markers or new therapeutic targets. Early-
expressed genes like those encoding the homeobox and
zinc-finger proteins play central roles in the regulation
of gene cascades and signal transduction pathways, and
thus the downstream effects of these pathways [21,22].
Thus, the primary goal of this study was to identify
genes that are differentially expressed at the pre-implan-
tation stages of embryonic development to establish
novel candidates for use in these broader applications.
We then assembled a comprehensive spatial and tem-
poral expression profile of the most promising genes
using DDRT-PCR (Figure 1). DDRT-PCR allows the sys-
tematic comparison of the expression of all mRNAs
among several cell populations. It has been used to
address biological questions in mammalian systems,
including cell differentiation, cell activation, cell stress,
and identification of drug targets [23]. The advantages
of DDRT-PCR over the traditional subtractive hybridiza-
tion and other comparative RNA techniques include (i)
rapidity and simplicity of assays, (ii) small quantities of
RNA, (iii) increased sensitivity, (iv) reproducibility, (v)
ability to identify differentially expressed genes in more
than one population, and (vi) ability to compare several
cell populations or variabless i m u l t a n e o u s l y .H o w e v e r ,
the assay does have its limitations, including false-posi-
tive results, the inability to confirm differential expres-
sion, and a reduced output compared to cDNA
microarrays.
Table 2 The effects of microinjection of different substrates into the cytoplasm of one-cell stage fertilized eggs on
early embryo developmental potential
Different substrate
treatment
Total embryo treated in
one-cell stage
†
No.(%) of survival embryo
after treatment
No.(%) of embryos developed to
2-cell
embryo
4-cell
embryo
8-cell
embryo
Morula
embryo
Blastocyst
embryo
2 mM granzyme G
Morpholino
80 43(53.8) 39(90.7)
a 5(11.6)
a 0(0.0)
a 0(0.0)
a 0(0.0)
a
2 mM control
Morpholino
90 45(50.0) 45(100.0)
ab
42(93.3)
b 42(93.3)
b 37(82.2)
b 26(57.8)
b
M2 buffer injection 46 20(43.5) 20(100.0)
ab
17(85.0)
b 17(85.0)
bc 17(85.0)
b 17(85.0)
c
Control embryo
(Uninjected)
74 – 74(100.0)
b 70(94.6)
b 57(77.0)
c 57(77.0)
b 57(77.0)
bc
† Six experiments were carried out in each group, and 10-15 embryos were used in each experiment.
abc Different superscripts within a column indicate a statistically significant difference (p < 0.05).
Table 3 The developmental potential of mouse embryos cultured in vitro after microinjection of different
concentrations of granzyme G antisense morpholinos into the cytoplasm of one-cell stage fertilized eggs
Dosage of Granzyme G
Morpholino
Total embryo treated in
one-cell stage
†
No. (%) of survival embryo
after treatment
No. (%) of embryos developed to
2-cell
embryo
4-cell
embryo
8-cell
embryo
Morula
embryo
Blastocyst
embryo
2 mM 64 31(48.4) 25(80.7)
a 7(22.6)
a 0(0.0)
a 0(0.0)
a 0(0.0)
a
0.2 mM 65 33(50.8) 32(97.0)
b 29(87.9)
b 25(75.8)
b 24(72.7)
b 11(33.3)
b
0.02 mM 81 45(55.6) 45(100.0)
b
45(100.0)
c 43(95.6)
c 43(95.6)
c 43(95.6)
c
0.002 mM 63 39(61.9) 38(97.4)
b 36(92.3)
bc 34(87.2)
bc 34(87.2)
bc 34(87.2)
c
† Six experiments were carried out in each group, and 10-15 embryos were used in each experiment.
abc Different superscripts within a column indicate a statistically significant difference (p < 0.05).
Tsai et al. BMC Developmental Biology 2010, 10:88
http://www.biomedcentral.com/1471-213X/10/88
Page 8 of 16Figure 6 The effect of inner cell mass (ICM) generation under low-dose anti-granzyme G morpholino treatment. Differential blastomere
staining of in vitro cultured blastocyst embryos at day 3.5: (A) normally developed embryo without MO treatment; (B) control nonsense MO-
injected embryo; (C, D) low-dose anti-granzyme G specific morpholino- (0.2 mM) injected embryos. The trophectoderm (TE) cells are stained with
pink fluorescence, and the ICM cells are stained with blue fluorescence. Scale bar: 30 μm. (E) Quantitative analysis of the numbers of total cells,
ICM cells, and TE cells plotted according to the different treatments: normal blastocyst (n = 10), M2 medium-injected embryos (n = 8), control
MO-injected embryos (n = 12), and low-dose anti-granzyme G-specific MO-injected embryos (n = 12).
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Page 9 of 16It is an interesting possibility that differential display
genes in pre-implantation embryos may help to “pull
the trigger” and initiate embryonic development and dif-
ferentiation. At the pre-implantation stages of embryo-
genesis, mammalian embryos undergo a so-called
“zygotic gene activation” or “embryonic gene activation”.
During this period, the activity of the embryonic gen-
ome changes significantly, and the nuclei begin to pro-
duce many new species of mRNA. Several important
genes listed in Table 1 are targets for functional studies
in early embryonic development. For example, the Snf2
h gene, which is expressed in 4-cell stage embryos,
encodes a protein with ISWI ATPase activity. A pre-
vious report has demonstrated that null Snf2h
-/-
embryos died during the preimplantation stage [24].
Blastocyst outgrowth experiments indicated that the loss
of Snf2 h results in growth arrest and cell death of both
the trophectoderm and inner cell mass. In the present
study, we successfully identified tweenty-three differen-
tially expressed genes in early mouse embryos (Table 1).
Among them, the granzyme G transcript encoding a ser-
ine protease was expressed at the 2-cell stage (Figures 2
and 3). It was previously reported that the differentia-
tion of mouse GMG cells, which begins at day 7 of
gestation, involves the accumulation of cytolytic media-
tors, including perforin and the serine protease gran-
zymes A-H, within cytoplasmic granules [19]. GMG
cells have been proposed to regulate trophoblast inva-
sion into maternal deciduas. Indeed, trophoblast killing
by murine and human uterine NK cells has been
reported [20]. Other previously proposed functions of
granzyme G include (i) the lysis of virus-infected cells
present in the uterus and placenta, (ii) the initiation of
abortion, (iii) the destruction of the extracellular matrix
and cells at the placenta/uterine interface to promote
parturition, (iv) nutritive functions, and (v) cytokine
Figure 7 Quantitation of zygotic RNA synthesis during the maternal-zygotic transition at the two-cell stage of the mouse embryo.( A
to D) Phase contrast images. (E to H) Images of a two-cell embryo treated with BrUTP and stained with Cy5-conjugated anti-BrdUTP antibody
(red). (I to L) mRNA expression profiles of the green lines presented in panels E, F, G, and H, respectively. (A, E, I) Two-cell stage embryo
following microinjection of granzyme G morpholino. (B, F, J) Two-cell stage embryo after injection of control morpholino. (C, G, K) Two-cell stage
of a normal embryo. (D, H, L) Two-cell stage embryo pretreated with a-amanitin, a transcriptional inhibitor, as a negative control. Scale bar: 25
μm.
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Page 10 of 16production [14,25]. However, there have been no reports
of the expression of granzyme G in 2-cell mouse
embryos or any conclusive data supporting a particular
biological function.
To determine the function of specific genes in the
field of developmental biology, many effective proce-
dures have been advanced to regulate or disrupt gene
expression. In early mouse embryos, researchers have
used a variety of methods, including antisense RNA,
double-stranded RNA interference, and gene knock-out
approaches [26,27] to block target gene expression and
assess the phenotype resulting from the deficiency. Anti-
s e n s eR N Ai so n eo fm o s tc o m m o nm e t h o d su s e dt o
down-regulate mRNA translation, especially in culture
systems. However, the potential of this technique was
unfulfilled until recently because the field was domi-
nated by the use of phosphorothioates, which are pla-
gued by unpredictable targeting, sensitivity to nucleases,
poor sequence specificity, and a host of non-antisense
effects [28]. The use of morpholino oligonucleotides
(MO) to suppress the translation of targeted genes is
proving to be a valuable tool for investigations of gene
function in zebrafish [29], Xenopus [30], and sea urchins
[31]. In mice, MOs have been applied to pre-implanta-
tion mouse embryos using the ethoxylated polyethyleni-
mine (EPEI) method [32] and in the germinal vesicle
stage of mouse oocytes by microinjection [33]. Both
methods successfully suppressed target gene expression.
We used this well-defined procedure to investigate the
function of granzyme G during pre-implantation devel-
opment in mouse embryos. In our preliminary test, con-
trol FITC-conjugated morpholino molecules that were
microinjected into 1-cell stage embryos were equally
distributed into dividing cells and stably retained until
the blastocyst stage (Figure 5).
I nt h en o n - s p e c i f i cM Ot o x i c i t yt e s t ,t h er e s u l t s
showed that embryonic development was not affected
by the introduction of a wide range of doses (1-20 mM)
of control morpholinos. Using the MO technique, we
further found that 2 mM granzyme G-specific MO
inhibited blastocyst formation in 100% of the treated
embryos (Table 2). The knock-down efficiency of the
MO treatment was measured using the RNase III pro-
tection assay [34]. RNase III is a RNA endonuclease that
specifically cleaves double-stranded RNAs, including the
complex formed by the antisense morpholino and the
endogenous sense mRNA, into small fragments. Semi-
quantitative RT-PCR analysis revealed that the degrada-
tion rates of granzyme G mRNA were 100%, 77%, and
0% after microinjection of pronuclear stage embryos
with 2 mM, 0.2 mM, and 0 mM of anti-granzyme G
morpholino, respectively (Figure 5B). In addition, the
microinjection of a serial dilution of granzyme G mor-
pholino into the cytoplasm of pronuclear mouse
embryos showed a dose-dependent inhibition of blasto-
cyst development rates (Table 3).
Figure 8 Embryo survival rate to pre-implantation developmental stages under different protease inhibitor treatments. Embryonic
development potential was evaluated by adding 2 mM PMSF (n = 30) or 0.1 mM 3, 4-DCI (n = 28) for granzyme-specific serine protease
inhibitors, 0.5 mM EDTA (n = 33) for non-granzyme-specific protease inhibitors, and 1% DMSO (n = 24) as a placebo control. A blank group (n =
30) that did not receive protease inhibitor was used to construct normal embryonic survival curves. The results are representative of three
experiments.
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expressed in pre-implantation embryos, such as the
seven-member family of subtilisin-like, calcium-depen-
dent serine proteases known as proprotein convertases
(PCs) [35]. In early embryos, PCs cleave a wide variety
of precursors into secreted peptides and proteins,
including hormones, neuropeptides, growth factors,
enzymes, membrane receptors, and extracellular matrix
proteins [36]. They have been implicated in most biolo-
gical processes affecting growth, development, and phy-
siology [37]. Indeed, several PC substrates are expressed
in pre-implantation embryos, such as precursors to
gonadotropin-releasing hormone (GnRH), transforming-
growth factors (TGF) b-1 and b-2, platelet-derived
growth factor (PDGF), and insulin-like growth factor 1
receptor (IGF1-R) [38,39]. Among these, GnRH has
been shown to be critical for normal pre-implantation
embryonic growth. ProGnRH mRNA and the GnRH
peptide are detectable in pre-implantation embryos from
the morula to the blastocyst stage [40]. Antisense inhibi-
tion of GnRH mRNA translation has been shown to
block the development of these embryos in vitro [38].
As proprotein convertase 1 (PC1) is the most likely
proGnRH convertase, it too may be important for pre-
implantation development at the morula stage, whereas
granzyme G appears to act in the maternal-zygotic tran-
sition at the 2-cell stage. As shown in the BrUTP incor-
poration experiment (Figure 7), treatment of embryos
with granzyme G-specific MO, as well as the transcrip-
tion inhibitor a-amanitin, inhibited RNA synthesis dur-
ing the maternal-to-zygotic transition.
To determine the effects of blocking granzyme G
activity in pre-implantation mouse embryos, we exposed
the developing embryos to three known protease inhibi-
tors: two serine protease-specific inhibitors and one
non-serine protease inhibitor [41,42]. Only the serine
protease-specific inhibitors, 3,4-DCI and PMSF, phe-
nocopied the MO-induced effect, blocking the maternal-
zygotic transition and dramatically decreasing the
embryo survival rate at the late 2-cell stage. However,
the metalloproteinase inhibitor, EDTA, had no such
effect (Figure 8). The effect of PMSF on different stages
of development was further evaluated in this study. Due
to the short life of PMSF activity, three different stages
of mouse embryos were separated and supplemented
one time with 2 mM PMSF in the culture medium. The
inhibition time window is only at the 2-cell stage, which
is the stage at which granzyme G functions as an active
serine protease in the embryos.
Oocytes, the female germ cells, contain all of the mes-
senger RNAs necessary to start a new life, but typically
wait until fertilization to begin development. The transi-
tion from oocyte to zygote involves many changes,
including protein synthesis, protein and RNA
degradation, organelle remodeling, and even the onset
of sexual differentiation [43-45]. Fifteen to thirty percent
of mRNA transcripts are degraded during zygote gene
activation [46]. Proteins are also targeted for degrada-
tion during the oocyte-to-zygote transition [47]. Protein
degradation often serves to inactivate proteins that are
needed early in the transition but that would be harmful
later [46]. Previous reports have demonstrated that two
serine protease inhibitors, Serpini 1 and Serpine 2, are
temporally expressed in the unfertilized egg and 1-cell
stage embryo, respectively [48,49]. These inhibitors may
prevent granzyme G function until the 2-cell stage,
where it regulates the maternal-zygotic transition. A
possible role for granzyme G in the maternal-zygotic
transition process is to participate in maternal protein
degradation and the subsequent initiation of zygotic
gene expression, as proposed in Figure 9. Dependence
on granzyme G activity was first observed at the early 2-
cell stage and persisted until the late 2-cell stage. This
responsiveness of the mouse zygote appears to require
new transcription from the zygotic genome [45].
Conclusion
This study has clearly demonstrated the feasibility of the
application of DDRT-PCR for the identification of tran-
scripts that are differentially expressed in mouse
embryos at various pre-implantation developmental
stages. Numerous novel transcripts have been identified
at the unfertilized egg, 2-cell, and 4-cell embryonic
stages. We characterized for the first time the expres-
sion of granzyme G during early stage embryogenesis.
Overall, our results suggest that granzyme G is an
important factor in early mouse development and may
play a novel role in the elimination of maternal proteins
and the triggering of zygotic gene expression during the
maternal-zygotic transition. Future studies will attempt
to determine the specific function and regulation of
these genes to enhance our understanding of normal
developmental events in very early embryos.
Methods
Collection of unfertilized mouse eggs and embryos at
various stages of early development
Eggs were collected from female ICR mice that were
intraperitoneally injected with 10 IU of pregnant mare
serum gonadotrophin (PMSG, China Chemical & Phar-
maceutical Co., Taiwan) to induce superovulation. After
48 hr, the mice were injected with 10 IU of human
chorionic gonadotrophin (hCG, China Chemical & Phar-
maceutical Co., Taiwan). All unfertilized oocytes were
collected 14-15 hr after the hCG injection in phosphate
buffered saline (PBS) containing 200 IU/ml of hyaluroni-
dase, to disperse cumulus cells, and were then trans-
ferred into human tubule fluid (HTF) medium (Irvine
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lized eggs, the superovulation-induced females were
mated with male ICR mice. The presence of a vaginal
plug on the subsequent morning (day 1) signified suc-
cessful mating, and time post-hCG was used to measure
the developmental age of the embryos. Embryos were
flushed from the oviducts using PBS buffer at 48 hr
post-hCG for the collection of 2-cell embryos and at 60
hr post-hCG for the collection of 4-cell embryos. The
collected embryos were washed three times with PBS
containing hyaluronidase and were then transferred into
HTF medium for further in vitro embryo culture or for
the extraction of total RNA [50]. The animal use proto-
col in this study has been reviewed and approved by the
Institutional Animal Care and Use Committee of the
National Chung Hsing University (IACUC Approval
number: 96-52).
RNA preparation and DDRT-PCR assay
Total RNA was prepared from pools of about 100
embryonic cells using the previously described guanidi-
nium acid-phenol method [51]. Isolated total RNA was
first subjected to reverse transcription (RT) using one of
the three anchor primers (H-T11-C, -G, or -A) and the
Superscript II RT kit (Gibco BRL, Grand Island, NY).
The quality of the total RNA and cDNAs were
examined using amplification of the house-keeping
gene, b-actin, as described [52]. This was followed by 35
thermal cycles of PCR using the original anchor primer
and one of the eight random primers, as shown in the
manufacturer’s description of the differential display
RNAimage system (GenHunter Co., Nashville, TN), in
t h ep r e s e n c eo f2μCi [a-
33P] dCTP (Amersham
Bioscience, Amersham, UK). PCR conditions were as
follows: 94°C for 30 sec, 32°C for 1.5 min, and 70°C for
1.5 min. The DDRT-PCR products were electrophoresed
in 8% denaturing polyacrylamide gels of 0.2-mm thick-
ness. After drying on a 3 MM filter, the gels were auto-
radiographed [52,53].
Sequence analysis, RT-PCR confirmation, and ribonuclease
protection assay
For re-amplification, bands of interest were excised, and
DNA was eluted from the gel by incubation of the gel
slice at 70°C in deionized water. PCR was performed
using aliquots of the recovered DNA fragment and the
same combination of anchor and random primers. The
PCR products were cloned into pGEM-T vector (Invi-
trogen, Carlsbad, CA) and sequencing was performed
using an automatic sequencer 373A (Applied Biosystems
Inc., Foster, CA). The differential display mRNA bands
were further confirmed by individual RT-PCR assays.
Figure 9 Proposed model for granzyme G action during mouse early embryonic development. Maternally produced proteins are
abundant in fertilized mouse eggs up to the early 2-cell stage, after which zygotic gene expression increases. Granzyme G, encoding a serine
protease, may contribute to this maternal-zygote exchange process. The genes marked with blue color were simultaneously presented in our
gene list (Table1) and in the previous report identified by cDNA microarray [49]. See the text for details.
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expression analysis were synthesized as follows: 5′-GAT
TCT CCT GAC CCT ACT TC-3′ (forward) and 5′-CTG
CGT GGT CTT GGA ATA GG-3′ (reverse). The b-
actin transcript was used as an internal RT-PCR control
and for the semi-quantitative quantitation of the gran-
zyme G RNA level as described previously [54,55]. The
ribonuclease protection assay (RPA) was performed by
first generating antisense RNA probes using the MAXI-
script in vitro transcription kit (Ambion, Austin, TX)
and the cloned DDRT-PCR products in the presence of
[a-
32P]UTP. The labeled gene-specific antisense RNA
was mixed with total RNA, and RPA analysis was car-
ried out using a commercial RPAII kit (Ambion, Austin,
TX).
Morpholino oligonucleotide synthesis and microinjection
The anti-granzyme G morpholino oligonucleotide (MO)
was designed and synthesized (Gene Tools, LLC, Philo-
math, OR) to be complementary to 25 bases of the
mouse granzyme G mRNA, lying downstream of the
initiation codon and containing the Kozak sequence.
The sequence of this MO was 5′-ATC AGG ATT GGT
GGC ATC TTC CCA G-3′. A fluorescent FITC-labeled
control nonsense MO with a random sequence, 5′-CCT
CTT ACC TCA GTT ACA ATT TAT A-3′,w a su s e d
to measure the MO distribution after cytoplasmic injec-
tion using Pieo (PMM 150FU, Prime Tech, Japan) and
to control for non-specific MO toxicity. In each experi-
mental trial, an additional control group was included
that consisted of embryos treated only with M2 med-
ium. Experimental groups often included embryo pools
that were not injected with MO or M2 medium and
served as normal controls. All experiments were con-
ducted a minimum of three times using embryos col-
lected from a minimum of three separate embryo
flushes.
Whole-mount in situ hybridization
The process of whole mount in situ hybridization of
mouse embryos was modified from Lefebvre et al. [56].
The zona pellucida was removed with Tyrode acid solu-
tion (pH 2.5) (Sigma, St. Louis, MO), and the embryos
were fixed in 4% formaldehyde, 10% acetic acid, 1 ×
PBS (100 mM Na2HPO4, 20 mM KH2PO4, 137 mM
N a C l ,2 7m MK C l ,p H7 . 4 )o na0 . 1 %p o l y l y s i n e - c o a t e d
cover slide for 30 min. After two PBS washes, the
embryos were permeabilized by treatment with 70%
ethanol overnight at 4°C. Following fixation, embryos
were rehydrated for 5 min at room temperature in 2 ×
SSC (300 mM NaCl, 30 mM sodium citrate, pH 7.0),
50% formamide and then were hybridized for 2-3 hr at
37°C in 200 μl of a mixture containing 10% dextran sul-
fate, 2 mM vanadyl-ribonucleoside complex, 0.02%
RNAse-free BSA, 40 μg E. coli tRNA, 2 × SSC, 15% for-
mamide, and 50 ng of granzyme G antisense oligonu-
cleotide probes. After hybridization, embryos were
washed twice for 30 min at the appropriate stringency
(2 × SSC, 50% formamide at 37°C). For DNA staining,
embryos were stained with 1 μg/mL Hoechst 33342
(Bisbenzimid, Sigma, St. Louis, MO) in PBS for 5 min
and washed twice with 1 × PBS. Cover slides were dried
and then transferred to the slide on a drop of mounting
oil. The excess mounting oil was aspirated, and the
cover slide was sealed with nail polish. The slides were
stored at 4°C or immediately observed using a fluores-
c e n c em i c r o s c o p e[ 5 5 ]o rac o n f o c a lm i c r o s c o p e
(LSM50, Carl Zeiss Meditec, Dublin, CA) [57].
Whole-mount immunofluorescence staining
The protocol of immunofluorescence staining was modi-
fied from our previous report [53]. Briefly, different
stages of mouse embryos were mounted on a 0.1% poly-
lysine-coated cover slide and stained with goat anti-
granzyme G antibody (sc-103533, Santa Cruz Biotech.
I n c . ,S a n t aC r u z ,C A ) ,w h i c hw a sd i l u t e d1 : 1 0 0 0w i t h
antibody dilutant buffer (1% BSA and 0.1% Triton-X
100 in PBS), followed by a secondary antibody of rabbit
anti-goat IgG-FITC. After washing, the stained embryos
were observed with a Carl Zeiss LSM5l0 confocal laser
scanning microscope with a 63 × objective lens.
Differential staining of inner cell mass (ICM) and
trophectoderm cells (TE)
To determine the total cell numbers and the ratio of
ICM to TE cells in granzyme G antisense MO-treated
(sub-inhibition dose) embryos, a differential staining
procedure was performed using a representative sample
of day 3.5 blastocysts, as previously described [58] with
minor modifications. Briefly, after removal of the zona
pellucida with Tyrode acid solution (pH 2.5), the
embryos were incubated in trinitrobenzene-sulfonic-acid
( T N B S ,S i g m a ,S t .L o u i s ,M O )f o r1 0m i no ni c e ,
washed in M2 medium, and incubated in 0.1 mg/ml
anti-dinitrophenyl-BSA (anti-DNP-BSA; ICN Biochem-
icals, Cleveland, OH) at 37°C for 10 min. After washing
in PBS+PVA, complement lysis was induced by incubat-
ing the embryos in guinea pig complement (Sigma, St.
Louis, MO), diluted 1:4 in PBS+PVA and supplemented
with 10 μg/ml propidium iodide (Sigma, St. Louis, MO),
at 37°C for 20 min, followed by brief washing and fixa-
tion in ice-cold ethanol. The inner nuclei were stained
with 0.05 mM Hoechst 33342 for 10 min. Stained
embryos were then mounted in 100% glycerol. Under a
fluorescence microscope, the outer TE cells were identi-
fied by the pink fluorescence of propidium iodide, while
the ICM cells were recognized by the blue fluorescence
of the bisbenzimide.
Tsai et al. BMC Developmental Biology 2010, 10:88
http://www.biomedcentral.com/1471-213X/10/88
Page 14 of 16In vivo RNA synthesis assay
A published protocol was used with some modifications
[59]. After granzyme G-MO, control-MO, or a-amanitin
treatment of 2-cell stage fertilized eggs (n = 20), bro-
mouridine (BrU; Sigma, St. Louis, MO) was added at
100 μM for 12 hr to label newly synthesized zygotic
RNA. The embryos were washed twice with 1 × PBS
and subjected to whole-mount in situ staining using
Cy5-conjugated anti-BrdU antibody (Roche Diagnostic).
The fluorescence quantification was performed using
t h es o f t w a r ef o rt h ec o n f o c a lm i c r o s c o p e( L S M 5 0 ,C a r l
Zeiss Meditec, Dublin, CA)
Statistical Analyses
Experiments were repeated at least three times with
embryo collection replicates. The collected data were
subjected to a chi-squared analysis using the statistical
analysis system, SAS, for multiple comparisons. Differ-
ences of p < 0.05(*) and p < 0.01 (**) were considered
statistically significant.
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